Know what to prove before you scale.
Customers want proof. Investors want customers. You cannot fund every next step.
By connecting the scientific evidence, the buying decision, delivery requirements and capital, I help you to see what to resolve first, what can wait and what would justify the next commitment.
For TTOs, investors and venture studios: continuing support across cases and cohorts. Scaleups can also work with me directly.
Bring the difficult case.
Keep the context.
More funding can buy time.
It cannot make a broken sequence work.
A CLOSER LOOK
A bigger batch can be a bigger unanswered question.
More production can scale downstream risk while buyer qualification remains unresolved.
WHAT CHANGES FOR YOU
Know what you are committing to — and why.
Before
The next move is driven by the next deadline.
Another pilot, another application, another round. The team stays busy while the question that matters to the buyer remains open.
After the work
The next commitment has a job to do.
You know which uncertainty the next step should resolve, what evidence would justify continuing and when to change course before committing more time and capital.
FOR TTOs, INVESTORS AND VENTURE STUDIOS
Bring the next case. Keep the context.
One independent adviser across your deep tech portfolio or cohort. Start with a case, keep the reasoning and return as evidence changes — without briefing someone new every time.
Agree the decision. Record the recommendation and the conditions for revisiting it. Review new cases at an agreed rhythm.
Leading a scaleup? You can commission the same work directly.
MY APPROACH
Good science deserves a commercial plan that can survive contact with reality.
The technology may work. That does not yet tell you who will adopt it, how they will qualify it, whether you can deliver it or which capital fits the route.
Evidence, Market, Industrialisation and Capital are examined together, including how the order of commitments changes the options left available. You get a recommendation specific to the case, with explicit conditions for proceeding, changing course or stopping.
The research behind this approach is developed through QUATISE®.
THE QUESTIONS THAT KEEP COMING BACK
If this sounds familiar, start here.
The funding route is becoming the business model.
Establish which capital fits the next useful proof and what commitments it creates. Keep credible commercial routes visible before funding terms narrow your options.
Every expert is right about their part.
Test whether the recommendations can work together. Resolve the dependency before your team commits to plans that cannot be delivered together.
The pilots keep going. The orders do not.
Identify the buying decision, its owner and the conditions still preventing commitment. Give the next pilot a purpose the customer recognises.
There are too many plausible markets.
Choose an initial route on evidence, adoption requirements and delivery realities. Know what to test first and what would justify changing that choice.
Start with one case. Build a continuing way of working.
Two levels of support. A separate capital strategy when you need it.
Venture Transition Review
You cannot justify the next commitment on the evidence you have.
Get an independent review of the binding constraint, credible routes and evidence gaps, with explicit conditions for proceeding in a 3–5 page Venture Decision Brief.
Your part: existing documents, up to three stakeholder conversations and one readout. Typical scope: 4–6 weeks.
Venture Transition Architecture
Your specialists have plans. Your venture still needs one route that holds together.
Get a commercial model and 12–24 month roadmap connecting the offer, buyer, adoption, pricing, industrialisation and capital, with dependencies and evidence gates.
Your part: existing material, targeted stakeholder introductions and a leadership workshop. Typical scope: 8–12 weeks.
Capital Acquisition Strategy
You need funding that advances the venture, without locking it into the wrong route.
Get a sequenced capital strategy, suitable funding sources and the evidence each step requires, aligned with technical and commercial milestones.
Your part: existing documents, one founder working session and a final readout. Typical scope: 2–3 weeks.
Book separately or alongside either tier.
Which commitment are you not yet comfortable making?
A short description of the case, the decision and the deadline is enough to begin.
Decisions changed
A promising result can still lead to the wrong next commitment. The cases show how evidence, market requirements, industrialisation and capital interact over time – and how a gap between them can redirect commercialisation. Explore where QUATISE identifies the underlying dependency, reshapes the next decision and clarifies who can add value. Download a case to compare the unchanged route with a practical alternative, including stakeholder Go, Hold and No-Go implications.
ELECTROCHEMICAL MATERIALS
Qualify the material before committing to production scale
An electrode-material venture is preparing to scale production on the strength of promising laboratory results. Its prospective customer still needs proof that the material performs in an assembled device.
Underlying issue: Production, assembly access and customer qualification are being planned separately. A larger batch could consume resources without producing the evidence needed for the next commercial decision.
Risk reduction: QUATISE connects representative samples, repeat batches, assembly access and customer acceptance into one qualification package. Compared with scaling first, this sequence can expose an unsuitable route before a larger commitment and clarify what evidence would justify proceeding.